據報跨國藥企尋求加入中國商業健康保險目錄以提高內地市場銷售
《彭博社》報道,多間跨國藥企正尋求通過加入中國商業健康保險目錄,擴大其創新高價藥物在內地的銷售。根據國家醫療保障局公布的文件,禮來(LLY.US)、諾和諾德及輝瑞(PFE.US)等公司已提交申請。
今年首度推出的商業健康保險目錄,專門收錄因價格過高未能進入國家醫保、但推薦由商業保險覆蓋的創新藥品,允許藥品以較小折扣幅度獲得報銷,為跨國企業開拓新銷售渠道。而此前藥企僅有兩種選擇,只可大幅降價進入國家醫保目錄,或局限於規模有限的私營市場。
報道指,共有121種藥物通過初步篩選進入候選名單,涵蓋暢銷藥及罕見病治療藥物,最終結果預計10至11月公布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.